43rd week of 2012 patent applcation highlights part 35 |
Patent application number | Title | Published |
20120269744 | ENHANCED PHOTOACTIVITY OF SEMICONDUCTORS AND/OR SUNSCREENS - A composition comprising a physical sunscreen, one or more adjuvants, and a carrier oil is provided. The composition also includes at least one of a compound having multiple phenyl groups, a film former or dispersant, and a silicone surfactant. The composition may also include an organic sunscreen. The combination of these ingredients exhibits an unexpected synergistic effect, in that the photoactive properties of the composition (e.g., SPF, UV absorption) are significantly higher than would be predicted based on the values for each of the components individually. | 2012-10-25 |
20120269745 | HYDROXYTYROSOL COMPOUNDS - A hydroxytyrosol polymer formed by either C—C coupling or C—O—C coupling is provided. Preferred polymers are formed by C—C coupling and the dimer has the following structure: (Formula I) (I) Compounds of the invention have been found to have antioxidant properties and their use in antioxidant compositions forms a further aspect of the invention. | 2012-10-25 |
20120269746 | USE OF CAPROLACTAM DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT - The present invention relates to the use of at least one caprolactam derivative of formula (I) below: in which: n=0 or 1; m=0 or 1; p=0 to 13; R | 2012-10-25 |
20120269747 | Novel Organopolysiloxane Copolymer - A novel organopolysiloxane copolymer is disclosed. The copolymer has excellent surface active power and exhibits excellent blending stability in cosmetic preparations and excellent feeling improvement characteristics in comparison to conventionally known polyether-modified silicones and silicone-containing alternating copolymers. The organopolysiloxane copolymer can be used in combination with various cosmetic formulation ingredients. The copolymer is an AB-type organopolysiloxane copolymer which has a silylalkyl group having a carbosiloxane dendrimer structure at one end of the molecular chain, and a hydrophilic segment at the other end. A method for producing the AB-type organopolysiloxane copolymer; a surfactant and a powder processing agent which are respectively composed of the organopolysiloxane copolymer; and a composition for external application and a cosmetic formulation which respectively contain the organopolysiloxane copolymer are also disclosed. | 2012-10-25 |
20120269748 | Thickening Or Gelling Agent For Oily Raw Materials - An excellent oil-thickening or -gelling agent is provided. The agent is compatible with various oils and can freely control the form or viscosity of oily raw materials or cosmetics by changing the quantity thereof added. The agent contains a novel co-modified organopolysiloxane that contains both a group having a siloxane dendron structure and a hydrophilic group and that preferably has a degree of polymerization of 200 or more. A gel composition containing the co-modified organopolysiloxane is also provided. The gel composition is useful as a base that permits stable and easy preparation of cosmetics having various viscoelasticities and forms. An oil is kept in the form of a gel that has a viscoelasticity falling within the intermediate range between the viscoelasticity of liquid and that of solid. Cosmetics containing the thickening or gelling agent are also provided. | 2012-10-25 |
20120269749 | COSMETIC COMPOSITIONS COMPRISING AN ESTER DERIVED FROM 4-CARBOXY-2-PYRROLIDINONE AND A MEROCYANIN SCREENING AGENT; USE OF SAID DERIVATIVE AS A SOLVENT FOR A MEROCYANIN SCREENING AGENT - The present invention relates to a composition comprising, in a cosmetically acceptable medium, at least one ester derived from 4-carboxy-2-pyrrolidinone, of formula (I) below: | 2012-10-25 |
20120269750 | COSMETIC COMPOSITIONS COMPRISING AN ESTER DERIVED FROM 4-CARBOXY-2-PYRROLIDINONE AND A LIPOPHILIC SCREENING AGENT; USE OF SAID DERIVATIVE AS A SOLVENT FOR A BENZOPHENONE LIPOPHILIC SCREENING AGENT - The present invention relates to a composition comprising, in a cosmetically acceptable medium, at least one ester derived from 4-carboxy-2-pyrrolidinone, of formula (I) below: | 2012-10-25 |
20120269751 | COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS - A composition for topical application includes at least one physiologically acceptable acid capable of reducing the pH of the skin of a treated person to the range of 1.5-4.5, and a physiologically acceptable carrier. Various uses for the treatment of skin and nail conditions are also disclosed, including and especially focusing on microbiological infections of the nail (onychomycosis). An applicator device and kit of parts comprising such a composition is also disclosed. | 2012-10-25 |
20120269752 | EMULSION CONTAINING A DISPERSION OF BISMUTH OXYCHLORIDE - The invention relates to a cosmetic composition in particular in the form of an emulsion for topical application to keratin materials, in particular the skin, comprising, in a physiologically acceptable medium:
| 2012-10-25 |
20120269753 | Semi-Permanent Cosmetic Concealer - A semi-permanent concealer composition for use on a target skin area that includes from about 10% to about 80% of a non-aqueous carrier from about 15% to about 35% of a tackifier comprising a tall oil glyceride, and from about 0.1% to about 20%, by weight, of colorant particles. The semi-permanent concealer composition is long lasting and has excellent wear characteristics. | 2012-10-25 |
20120269754 | Low Flash Point Lip Composition Containing Solvents of Varying Evaporation Rates - Described herein is a cosmetic composition comprising a mixture of volatile solvents with varying evaporation rates, wherein at least two of the volatile solvents are in combination with a film former. A single application of a cosmetic composition as described herein provides transfer resistance, long wear, and comfort and as such, may be used in lipsticks, lip glosses, mascara, hair care products, and other such cosmetics for which transfer resistance, long wear and comfort are desired properties. | 2012-10-25 |
20120269755 | Lip Cosmetics - The present invention provides a lip cosmetic that has excellent secondary adhesion resistance effect immediately after the application and is excellent in gloss and stability. The lip cosmetic of the present invention is characterized by comprising the following (a) and (b), wherein the blending quantity of (b) is 20 to 70 mass %:
| 2012-10-25 |
20120269756 | PROCESS FOR INHIBITING DYED HAIR FIBERS FROM LOSING THEIR COLOR DURING SHAMPOOING - A process for inhibiting dyed hair fibers from losing their color during shampooing involving contacting the dyed hair fibers with a composition containing: (a) at least one polyamine compound having at least two amino groups; (b) at least one anionic silicone; and (c) optionally, at least one surfactant, and wherein (a) is present in the composition in an amount sufficient to inhibit the dyed hair fibers from losing their color during shampooing. | 2012-10-25 |
20120269757 | PRODUCTS FOR KERATIN FIBERS, CONTAINING AT LEAST ONE SPECIAL AMPHIPHILIC CATIONIC POLYMER AND AT LEAST ONE SPECIAL CATIONIC POLYMER HAVING VINYLIMIDAZOLE STRUCTURAL UNITS - Agents for treating keratin-containing fibers, particularly human hair, containing in a cosmetically acceptable carrier (a) at least one amphiphilic, cationic polymer having at least one structural unit of formula (I), at least one structural unit of formula (II) and at least one structural unit of formula (III), | 2012-10-25 |
20120269758 | HAIR STYLING - System and method for styling hair, characterized by a composition comprising about 1 to about 10 wt % of cysteamine, or a cosmetically acceptable derivative thereof as a primary reducing agent; and a composition comprising about 0.01% to about 2 wt. % of hydrogen peroxide, a cationic silicone compound, and a fatty acid ester. | 2012-10-25 |
20120269760 | Eye Drops - An eye drop composition comprising a carboxyvinyl polymer and a monoterpene, and having a viscosity from 200 to 100,000 mPa·s. The monoterpene may be at least one selected from the group consisting of menthol, camphor and borneol. The carboxyvinyl polymer content may be from 0.001 to 10 w/v % with respect to the total volume of the eye drop composition, and the monoterpene content may be from 0.0001 to 1 w/v % with respect to the total volume of the eye drop composition. | 2012-10-25 |
20120269761 | BIODEGRADABLE ELASTOMERS - The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers. | 2012-10-25 |
20120269762 | CAUSAL THERAPY OF DISEASES OR CONDITIONS ASSOCIATED WITH CNS OR PNS DEMYELINATION - The invention broadly relates to the use of the Active in the causal treatment of a disease caused by axonal demyelination, in which the Active maintains the integrity of myelination (for example by promoting remyelination, and/or preventing demyelination, of the axonal sheaths). The invention is particularly directed to the causal treatment of CNS demyelination diseases, for example MS, especially primary progressive MS and/or relapse remitting MS, and PNS demyelination diseases, for example Charcot-Marie-Tooth Disease. The Active of the invention may be suitably administered when a patient is in relapse (i.e. upon relapse), and be continued while the patient is in relapse, with a view to attenuating the severity of the relapse, and/or accelerating disease remission. Alternatively, the Active may be administered continuously with a view to prolonging the remission period, and/or attenuating the severity of the relapse, and/or preventing relapse. The invention also relates to the use of the Active as a treatment for symptoms of demyelination disease, especially MS, selected from vision deficits, motor control deficits, and sensation deficits. | 2012-10-25 |
20120269763 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF PRETERM LABOR - The present invention provides compositions, kits and methods for the prevention of spontaneous abortion or implantation failure during assisted reproduction. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent spontaneous abortion or implantation failure of an embryo. The present invention also provides compositions, kits and methods for the treatment or prevention of preeclampsia and preterm labor. | 2012-10-25 |
20120269764 | RBM3 as a Marker for Malignant Melanoma Prognosis - A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group. | 2012-10-25 |
20120269765 | CYTOKINE COMPOSITIONS AND METHODS OF USE THEREOF - Polypeptides, including non-naturally occurring and recombinantly modified polypeptides related to the p19 subunit of IL-23, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided. | 2012-10-25 |
20120269766 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS - The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-H′ function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-H's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein. | 2012-10-25 |
20120269767 | Treatment of Neurodegenerative Diseases - The present specification discloses beta-amino alcohols and methods of treating a neurodegenerative disease using such compounds. | 2012-10-25 |
20120269768 | ANTIVIRAL PRODUCT - The present invention relates to a novel antiviral product, its use in the treatment of hepatitis C, and its process of manufacture. More particularly it relates to a characterised product exhibiting antiviral activity against Hepatitis C virus (HCV). In one embodiment there is provided a single herb | 2012-10-25 |
20120269769 | Hepatitis C Inhibitor Compounds - Compounds of formula (I): | 2012-10-25 |
20120269770 | Stable Preserved Compositions of Interferon-Beta - Stable preserved compositions of interferon-β and pegylated-interferon-β are described. | 2012-10-25 |
20120269771 | SIALOCHIMERIC COMPOUNDS - The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health. | 2012-10-25 |
20120269772 | LIPID DEPOT FORMULATIONS - The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament. | 2012-10-25 |
20120269773 | RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE TRANSPORTER (NIS) - The present invention relates to the field of gene therapy and the treatment of tumors. | 2012-10-25 |
20120269774 | ALLOGENEIC STEM CELL TRANSPLANTS IN NON-CONDITIONED RECIPIENTS - Methods, cells, and compositions of matter are disclosed for performing stem cell transplants in patients that have not been previously immunosuppressed. Specific disclosed are methods of matching, methods of treating the stem cell graft, and use of engraftment-assisting cells and agents. | 2012-10-25 |
20120269775 | Adipose Stromal Stem Cells For Tissue And Vascular Modification - Methods are provided for promoting angiogenesis in a mammal, such methods including the administration of therapeutic quantity of adipose-derived stromal cells to a mammal such that therapeutic angiogenesis occurs. | 2012-10-25 |
20120269776 | PRODUCTIONS OF ARTIFICIAL TISSUES BY MEANS OF TISSUE ENGINEERING USING AGAROSE-FIBRIN BIOMATERIALS - The present invention is encompassed in the field of biomedicine and more specifically tissue engineering. It relates specifically to an in vitro method for preparing an artificial tissue, to the artificial tissue obtainable by said method and to the use of this artificial tissue to partially or completely increase, restore or replace the functional activity of a damaged tissue or organ. | 2012-10-25 |
20120269777 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 2012-10-25 |
20120269778 | METHODS OF GENERATING NEURAL STEM CELLS - The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure. | 2012-10-25 |
20120269779 | MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders. | 2012-10-25 |
20120269780 | Method For Preparing an Acellular Organic Tissue of Human or Animal Origin For Revitalization - The invention concerns a method for the preparation of an acellular organic tissue for revitalization, in particular for the introduction of living cells, comprising a stage in which the acellular organic tissue ( | 2012-10-25 |
20120269781 | METHOD FOR PROLIFERATING HAIR FOLLICLE STEM CELLS - The present invention relates to a method of proliferating follicular stem cells in high yield, and more particularly, to a method of proliferating follicular stem cells in large amounts by culturing the cells using a specific medium containing a specific concentration of a Rho-associated kinase (ROCK) inhibitor and to a medium which is used in the method. | 2012-10-25 |
20120269782 | MATERIALS AND METHODS FOR GENERATING PLURIPOTENT STEM CELLS - The present invention relates to a method of reprogramming a somatic cell to produce an induced pluripotent stem (iPS) cell which is capable of differentiating into somatic cells derived from ectoderm, mesoderm or endoderm. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells. | 2012-10-25 |
20120269783 | COMPOSITION CONTAINING AUTOLOGOUS MONONUCLEAR CELLS AND PIG COLLAGEN SCAFFOLD IN PASTE FORM AND ITS USE IN THE PREPARATION OF A MEDICAMENT FOR SURGICAL TREATMENT - Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments. | 2012-10-25 |
20120269784 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for method of treating a subject having reduced cardiac function or cardiac disease by administering adult bone marrow-derived stem cells to an individual. In some embodiments, the subject is a myocardial infarction patient or congestive heart failure patient. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 2012-10-25 |
20120269785 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN CANINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection. | 2012-10-25 |
20120269786 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN FELINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection. | 2012-10-25 |
20120269787 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN EQUINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection. | 2012-10-25 |
20120269788 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 2012-10-25 |
20120269789 | GROWING UP MILKS CONTAINING PROBIOTIC MICRO-ORGANISMS - The present invention relates to the field of nutrition for infants and young children. In particular, the present invention relates to growing-up milks comprising probiotic micro-organisms to be administered to infants and young children older than 10 months. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example. | 2012-10-25 |
20120269790 | USE OF PLANT EXTRACTS AS PREBIOTICS, COMPOSITIONS AND FOODS CONTAINING SUCH EXTRACT - The present invention claims the use of pomegranate (Punica granaturn) plant extracts and various combinations of said extracts, some additionally including a probiotic, which allow a synergistic effect between the bioactive components thereof, for the purpose of preparing dietary supplements, functional foods/beverages, food additives and drugs for use in caring for human health. | 2012-10-25 |
20120269791 | Treatment Of IBD And IBS Using Both Probiotic Bacteria And Fermented Cereal As Treatment Effectors - The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease. | 2012-10-25 |
20120269792 | EUTECTIC-BASED SELF-NANOEMULSIFIED DRUG DELIVERY SYSTEM - A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ | 2012-10-25 |
20120269793 | PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF HAIR LOSS - Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with hair loss or prostate cancer/prostate hypertrophy are described herein. These select phytoestrogen formulations are preferably composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in non-reproductive tissues including brain. | 2012-10-25 |
20120269794 | NUTRACEUTICAL COMPOSITION THAT COMPRISES EXTRACT OF SHILAJIT, FOLIC ACID, VITAMIN B12 AND VITAMIN B6 AND THE USE THEREOF FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISEASES AND/OR THE COGNITIVE DETERIORATION ASSOCIATED WITH CEREBRAL AGEING - The present invention relates to a potent antioxidant neuroprotective nutraceutical composition that comprises blending extract of Shilajit (250 to 500 mg) and folic acid (200 to 400 μg), together with small amounts of vitamins B6 (20 to 40 μg) and B12 (4 to 8 μg) consumed per day. This composition can be used to prevent and to treat neurodegenerative diseases or episodes of cognitive deterioration arising from various pathological conditions. The use thereof is indicated in the treatment of Alzheimer's disease and senile dementia as the pathological conditions preferably to be treated. The composition is suitable for direct human consumption by mouth, either in solid form as a powder or as a suspension of the extract, as a food additive or as a nutraceutical agent. It may be formulated as a nutraceutical agent to be included as an ingredient in beverages or as a drug in conjunction with permitted excipients. | 2012-10-25 |
20120269795 | HUMANIZED RECOMBINANT URICASE AND MUTANTS THEREOF - The present invention provides a humanized recombinant uricase and mutants thereof, wherein the humanized recombinant uricase is a chimeric protein which comprises amino acids of non-human mammal uricase and amino acids of human uricase. The humanized recombinant unease and mutants thereof have reduced immunogenicity in human, and can be used for the treatment of hyperuricemia and gout. | 2012-10-25 |
20120269796 | Method for Enhancing Pancreatic Beta Cell Proliferation, Increasing Serum Insulin Concentration, Decreasing Blood Glucose Concentration And Treating And/Or Preventing Diabetes - By enhancing the function of ERK proteins in the liver, proliferation of pancreatic β cells is promoted, blood insulin concentration increased, blood glucose level decreased, and diabetes is prevented and/or treated. The methods for enhancing the function of ERK proteins in the liver are not particularly limited, and include various aspects such as enhancement of activity of MEK proteins, activation of endogenous MEK proteins, administration of an expression vector which expresses a gene encoding an active-form of MEK protein, and the like. | 2012-10-25 |
20120269797 | METHOD FOR INHIBITING THE MATURATION OF DENDRITIC CELLS - Proteasome inhibitors (PI) are used for inhibiting the maturation of dendritic cells (DZ) and thus in the treatment or the prophylaxis of allergies, asthma, tissue or transplant rejection or autoimmune diseases. The concentration of the proteasome inhibitors lies preferably in the range of 10 nM to 10 μM, based on the peripheral blood or the cytoplasm. | 2012-10-25 |
20120269798 | ENHANCEMENT OF REGENERATION BY MODULATION OF NOTUM ACTIVITY - The invention provides compositions and methods of use for identifying modulators of NOTUM, e.g., NOTUM inhibitors. In some aspects, identified compounds are useful for modulating Wnt signaling at sites of tissue damage. The invention further provides methods of promoting regeneration by inhibiting NOTUM. | 2012-10-25 |
20120269799 | DIAGNOSTIC AND TREATMENT METHODS USING A LIGAND LIBRARY - The invention relates to diagnostic and treatment methods using a ligand library. Specifically, the invention relates to using a ligand library to diagnose or detect a drug induced response, including drug adverse reaction, side effects, drug resistance, and therapeutic efficacy. The invention further relates to identifying biomarkers associated with a drug induced response and providing a personalized medical treatment. | 2012-10-25 |
20120269800 | Anti-neoplastic compositions comprising extracts of black cohosh - A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na | 2012-10-25 |
20120269801 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE AND PATHOGENIC DISEASES - The invention features proteins including an antibody, or functional derivatives thereof, that bind hCD59 and have the activity of domain 4 of the | 2012-10-25 |
20120269802 | Treatment And Prognosis With Thalidomide In Multiple Myeloma Based on Karyotyping And Gene Expression Profiling - The present invention provides a method treating a myeloma patient by administering one or more of thalidomide, a Total Therapy 2 regimen, an interleukin-6 signaling suppressor, an interleukin-6R signaling suppressor, an IGF1 signaling suppressor, an IGF1 R signaling suppressor, shRNA or other modulators of gene expression. Also, provided are methods for predicting outcome of a treatment for an individual having a cancer, e.g., myeloma, by performing one or more of karyotyping or expression profiling of chromosomes 1 and 13 or expression level measurement of IL-6R. | 2012-10-25 |
20120269803 | SUBSTITUTED BENZOSULPHONAMIDES - The present invention relates to substituted benzosulphonamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 2012-10-25 |
20120269804 | SUBSTITUTED BENZOSULPHONAMIDES - The present invention relates to substituted benzosulphonamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 2012-10-25 |
20120269805 | ANTIBODIES DIRECTED AGAINST AMYLOID-BETA PEPTIDE AND METHODS USING SAME - Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer's disease and Aβ peptide associated diseases are described. Methods of using antibodies directed against amyloid-beta peptide having impaired effector function for treatment of Alzheimer's disease and Aβ peptide associated diseases are also described. | 2012-10-25 |
20120269806 | METHODS OF INDUCING TOLERANCE - Methods of inducing tolerance, and promoting graft acceptance, are described herein. The methods include administering to a recipient hematopoietic stem cells and an agonist of Programmed Death 1 (PD-1). | 2012-10-25 |
20120269807 | COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY OF lgG-DECOY RECEPTOR FUSION PROTEINS - Provided herein are compositions and related methods for delivering an IgG-decoy receptor to the CNS. The methods include systemic administration of a bifunctional decoy receptor-BBB receptor antibody fusion antibody comprising a receptor extracellular domain (ECD) covalently linked to an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor). In some embodiments, the compositions described herein are administered to treat a subject suffering from a CNS condition. | 2012-10-25 |
20120269808 | METHODS AND COMPOSITIONS FOR MODULATING TWEAK AND FN14 ACTIVITY - Agonists and antagonists which modulate the activity of TWEAK and TWEAK receptor are provided. The methods, compositions and kits of the invention may be employed in the treatment of disorders such as cancer and immune-related diseases. | 2012-10-25 |
20120269809 | TNFalpha-Neutralizing Antibodies - The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications. | 2012-10-25 |
20120269810 | METHODS AND COMPOSITIONS FOR PANIC DISORDERS - Methods and compositions that down regulate the activity of orexins to treat panic disorder and panic-like responses associated with hypercapnic conditions are disclosed. | 2012-10-25 |
20120269811 | HUMANIZED FC GAMMA RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB. | 2012-10-25 |
20120269812 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 2012-10-25 |
20120269813 | POLYCLONAL BISPECIFIC ANTIBODY COMPOSITIONS AND METHOD OF USE - The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided. | 2012-10-25 |
20120269814 | ANTI-C MPL ANTIBODIES - The present invention provides compositions and methods utilizing antagonistic antibodies which specifically bind to human c-MPL (e.g., TPO-R). | 2012-10-25 |
20120269815 | NEUROTROPHINS AND USES THEREOF - A neurotrophin polypeptide, and a biologically active fragment thereof, are described. Also, methods are disclosed that include providing a composition comprising the neurotrophin polypeptide to a subject, wherein the composition is effective to ameliorate at least one symptom or clinical sign of a condition treatable with a neurotrophin when the composition is administered to a subject in need of treatment for a condition treatable with a neurotrophin. | 2012-10-25 |
20120269816 | Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor-I - The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same. | 2012-10-25 |
20120269817 | Monoclonal Antibodies Against Tissue Factor Pathway Inhibitor - Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided. | 2012-10-25 |
20120269818 | METHODS FOR TREATING INFECTION BY HPV - We describe herein methods for treating HPV infections and medical conditions caused by HPV infections. Generally, the methods include administering to a subject exhibiting at least one symptom or clinical sign of HPV infection a composition that includes an EGFR signaling inhibitor in an amount effective to ameliorate the at least one symptom or clinical sign of HPV infection. | 2012-10-25 |
20120269819 | Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors - This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided. | 2012-10-25 |
20120269820 | ANTI-IL 17A/IL-17F CROSS-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF - This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2012-10-25 |
20120269821 | HIV-1 ANTIBODIES - The present invention relates, in general, to HIV-1 antibodies and, in particular, to broadly neutralizing HIV-1 antibodies that target the gp41 membrane-proximal external region (MPER). | 2012-10-25 |
20120269822 | Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies - Antibodies that bind to | 2012-10-25 |
20120269823 | VIRULENT ISOLATE OF NEOSPORA CANINUM AND ITS USES - The present invention relates to a new isolate of | 2012-10-25 |
20120269824 | THERAPEUTIC HUMAN ANTI-IL-1R1 MONOCLONAL ANTIBODY - Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described. | 2012-10-25 |
20120269825 | METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER - Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L. OX40L inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. It has been shown that signaling the OX40-receptor on human T cells by antibodies, small molecules, or the OX40L modulates the generation and function of IL-10 producing Foxp3 | 2012-10-25 |
20120269826 | ANTI-CD3 ANTIBODY DOSING IN AUTOIMMUNE DISEASE - Provided herein are methods of administering anti-CD3 antibodies or antigen-binding fragments thereof to an animal. In certain embodiments, the anti-CD3 antibody or fragment thereof does not bind or has reduced binding to at least one class of Fc (gamma) receptors. In certain embodiments, the animal has an immune-related disease. | 2012-10-25 |
20120269827 | Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube Cancer - The present invention relates to highly effective anti-cancer drug combinations, pharmaceutical compositions comprising the same, and uses thereof in the treatment of ovarian, peritoneal, or fallopian tube cancer. In particular, the present invention is based on the discovery that the administration of a CD56 antibody linked to a cytotoxic compound (e.g., an immunoconjugate) in combination with a chemotherapeutic agent (in particular a gemcitabine compound, a topotecan compound, and a doxorubicin compound), improves the therapeutic index in the treatment of ovarian, peritoneal, or fallopian tube cancer over and above the additive effects of the anticancer agents used alone. In one embodiment of the invention, combinations of the CD56 antibody, or fragment thereof, linked to a cytotoxic compound plus an additional chemotherapeutic agent have a synergistic effect in the ovarian cancer therapeutic index. | 2012-10-25 |
20120269828 | ANTI-DRUG VACCINES - The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject. | 2012-10-25 |
20120269829 | Inhibitors of Phosphatase and Tensin Homolog (PTEN) Compositions, Uses and Methods - Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease. | 2012-10-25 |
20120269830 | CONJUGATES WITH IMPROVED PHARMACOKINETIC PROPERTIES - The present invention concerns methods and means for modulating pharmacokinetic properties of molecules, such as biologically active molecules. More specifically, the present invention concerns conjugates comprising a biologically active moiety and a moiety conjugated to and modulating at least one pharmacokinetic property of the biologically active moiety (pharmacokinetic property modulating moiety). | 2012-10-25 |
20120269831 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF - Compounds useful as antiproliferative agents according to Formula (I), wherein n, A, R | 2012-10-25 |
20120269832 | Mature Dendritic Cell Compositions and Methods of Culturing Same - This invention provides novel CD40L polypeptides and nucleic acids, as well as antigen presenting cells and vaccines comprising such CD40L polypeptides and/or nucleic acids, and related methods for preparing the antigen presenting cells and vaccines. The antigen presenting cells and vaccines are useful for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g., mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface. | 2012-10-25 |
20120269833 | ALLORESTRICTED PEPTIDE-SPECIFIC T CELLS - The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL | 2012-10-25 |
20120269834 | IMMUNOGLOBULIN CLEAVAGE FRAGMENT VACCINE COMPOSITIONS - The invention relates to methods and reagents for the preparation and use of a therapeutic immunospecific for IgG breakdown products retaining antigen binding but having lost effector functions. The reagents of the invention may be used as immunogens for the purpose of prophylactic or therapeutic vaccination of a human subject. | 2012-10-25 |
20120269835 | PROCESS FOR THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS - The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3. | 2012-10-25 |
20120269836 | Vaccine - Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence | 2012-10-25 |
20120269837 | SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb) - This invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either FcγRIIb and FcγRIIa. | 2012-10-25 |
20120269838 | CARRIER CONJUGATES OF IL-23-PEPTIDES AND THEIR INDUCED ANTIBODIES - The present invention relates to a pharmaceutical composition comprising as active substance, at least one compound comprising, or consisting of, a polypeptide which comprises, or consists of, at least 11 contiguous amino acids selected from X | 2012-10-25 |
20120269839 | HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS - A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions. | 2012-10-25 |
20120269840 | EXPRESSION OF HIV POLYPEPTIDES AND PRODUCTION OF VIRUS-LIKE PARTICLES - The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered. | 2012-10-25 |
20120269841 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF - In one aspect, the invention relates to an immunogenic composition that includes a mutant | 2012-10-25 |
20120269842 | ENTEROTOXIGENIC E. COLI FUSION PROTEIN VACCINES - The disclosure relates to fusions of enterotoxigenic | 2012-10-25 |
20120269843 | S. EPIDERMIDIS ANTIGENS - Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of | 2012-10-25 |
20120269844 | VACCINES FOR THE TREATMENT OF NEOPLASIAS FROM VIRAL CAPSIDS OF BIRNAVIRUS CONTAINING ANTIGENS OF THE HUMAN PAPILLOMAVIRUS - The invention relates to therapeutic vaccines for the treatment of neoplasias caused by the human papillomavirus (HPV). In particular, the vaccines of the present invention are formed by chimeric virus-like capsids of birnavirus containing papillomavirus antigens. | 2012-10-25 |